Hydrolytic Enzymes Targeting to Prodrug/Drug Metabolism for Translational Application in Cancer

Authors: Prabha M*

Volume 1, Issue 1

Abstract

A variety of approaches are under development to improve the effectiveness and specificity of enzyme activation for drug metabolism on tumour cell targeting for cancer treatment. Many such methods involve conjugates like monoclonal antibodies, substrate specificity and offer attractive means of directing to tumour toxic agents such as drugs, radioisotopes, protein cytotoxins, cytokines, effector cells of the immune system, gene therapy, stem cell therapy and enzyme therapy for therapeutic use. Hydrolytic enzymes belong to class III of enzyme classification and play an important role in the drug metabolism towards the treatment of cancer. Hydrolases helps drugs for metabolic efficiency to target on cancer cell since it is involved in the hydrolytic reaction of various biomolecules and compounds. The prodrug is designed to be a substrate for the chosen enzyme activity. A number of prodrugs have been developed that can be transformed into an active anticancerous drugs by enzymes of both mammalian and non mammalian origin. The basic molecular biochemistry, biotechnological processes and other information related to enzyme catalysis, has a major impact for the production of efficient drugs. In the current review some of the Hydrolases has been discussed which play a significant role towards prodrug to drug metabolism for cancer treatment. 

Keywords:

Carboxylesterases; Alkaline phosphatases; β-Glucosidase; βglucuronidase; Carboxy peptidase; Matrix metalloproteinases; Epoxide hydrolases; Cancer; Hydrolases; Drug metabolism 

 

 

View PDF